A new map of menopause raises a question that reaches beyond reproductive health: which clock should aging research use? Calendar age is convenient, but it can place people experiencing different biological transitions on the same timeline. A study published October 12 in Nature Medicine attempts to recover the changes that this averaging can conceal.
Researchers led by Uri Alon at the Weizmann Institute of Science analyzed US and Israeli datasets containing more than 300 million laboratory tests. Their computational reconstruction aligns population patterns around the final menstrual period and identifies abrupt shifts across several physiological systems. The authors describe a physiological cliff. Their algorithm explicitly does not predict an individual’s final menstrual period.
TENS Magazine’s analysis is that the useful advance is a better research calendar. A sharper population curve can help investigators decide when to look and what to measure. Turning it into a personal countdown would require a different kind of evidence. Comparing this new map with longitudinal menopause research shows why both approaches are needed.
A calendar that preserves the event
Imagine two participants whose final menstrual periods occur years apart. Grouping their measurements by birthday places the transition at different points. Grouping them by distance from that event asks a more focused question. The first timeline describes age patterns; the second can help reveal changes organized around a shared biological transition.
The new study uses a statistical reconstruction because the event date is often missing. It estimates average laboratory trajectories from cross-sectional data using the distribution of menopause ages. Agreement between the two populations strengthens the research signal, but the reconstructed trajectory is still an estimate of population behavior.
For research infrastructure, the implication is concrete: recording reproductive stage and event timing can be as consequential as collecting another biomarker. TENS would judge a future aging dataset partly by whether it preserves these coordinates. Without them, an apparent difference between two samples could mix biological timing with the phenomenon investigators actually want to study.
This also changes how a model should be evaluated. A system that estimates the average transition well may still give poor individual forecasts. Those are separate tasks with separate errors. Any proposed personal prediction tool would need testing against subsequently observed events, with uncertainty reported for people whose trajectories differ from the average.
Different measurements can tell different stories
The Study of Women’s Health Across the Nation provides a useful comparison. In a 2019 JCI Insight paper, Gail Greendale and colleagues examined repeated body-composition measurements in 1,246 women relative to their final menstrual period. Fat gain accelerated and lean mass declined during the transition, while total weight did not show the same acceleration.
That finding gives the new laboratory map a practical interpretive test. Before asking whether menopause is abrupt or gradual, specify the measurement. A change in the balance of tissues can coexist with a smoother total-weight curve. Likewise, a shift in a laboratory value and the onset of a disease are different events. Neither should silently stand in for the other.
The two studies therefore contribute complementary resolutions. The new reconstruction surveys many biological measures across large datasets. SWAN’s repeated observations track changes within participants. In TENS’s assessment, the strongest next step is to compare both approaches on the same measures, rather than treating the larger database as a replacement for detailed follow-up.
Such a comparison could ask whether a reconstructed turning point appears when the same people are followed through it. It could also test whether the timing differs across groups. Where results disagree, researchers would have a specific discrepancy to investigate: the measure, the population, the event dating or the modeling assumptions.
Keep the clinical question separate
The Nature Medicine analysis also reports smaller shifts in many measures among menopausal hormone therapy users. This was observational evidence. The authors acknowledge that statistical adjustment cannot remove every difference between users and nonusers, including differences connected to access to care.
A smoother laboratory trajectory should therefore not become a synonym for longer life or preserved function. Those outcomes need their own measurements and suitable comparisons. The study does not establish that changing these markers extends lifespan or healthspan, and it supplies no basis here for a treatment recommendation.
For longevity research, this distinction suggests a sequence of questions. First establish whether a transition-associated pattern reproduces. Then determine whether it improves understanding or prediction of meaningful outcomes beyond existing information. Only an appropriately designed intervention study can establish whether deliberately changing the pattern produces benefit. Success at an earlier stage cannot answer a later one by implication.
The scientific opportunity is to make midlife studies more precise without making women’s futures sound predetermined. Both the new computational study and the older longitudinal work concern human observational evidence, with different strengths and limitations. Together they support a research agenda built around event timing, specific measurements and follow-up—not a universal date at which every person’s health changes course.
TENS Magazine conceptual illustration
